Running Oak Capital LLC Lowers Position in Icon Plc $ICLR

Running Oak Capital LLC trimmed its holdings in shares of Icon Plc (NASDAQ:ICLR) by 8.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,335 shares of the medical research company’s stock after selling 8,883 shares during the period. Icon comprises about 1.9% of Running Oak Capital LLC’s portfolio, making the stock its 16th largest position. Running Oak Capital LLC owned approximately 0.12% of Icon worth $17,209,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ICLR. Private Trust Co. NA boosted its stake in shares of Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 94 shares in the last quarter. Ameritas Advisory Services LLC purchased a new stake in Icon during the second quarter worth $48,000. Wilmington Savings Fund Society FSB boosted its position in Icon by 153.4% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 201 shares in the last quarter. LRI Investments LLC purchased a new position in shares of Icon in the 2nd quarter valued at $49,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in shares of Icon in the 3rd quarter worth $63,000. Institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ICLR. Barclays raised their price objective on Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. UBS Group set a $220.00 price objective on shares of Icon in a research report on Friday, October 24th. TD Cowen boosted their price objective on shares of Icon from $172.00 to $183.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Leerink Partners restated an “outperform” rating on shares of Icon in a research note on Monday, January 5th. Finally, Mizuho set a $216.00 price target on shares of Icon in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Icon has an average rating of “Hold” and an average target price of $200.60.

Icon Price Performance

Shares of ICLR opened at $178.59 on Tuesday. The business’s 50-day moving average is $184.24 and its two-hundred day moving average is $177.07. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market capitalization of $14.42 billion, a P/E ratio of 24.17, a P/E/G ratio of 3.81 and a beta of 1.26. Icon Plc has a fifty-two week low of $125.10 and a fifty-two week high of $211.00.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.